Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia
Ángel Arenal(Hospital General Universitario Gregorio Marañón), Antonio Berruezo(Hospital Quirón Teknon), David Calvo(Centro de Investigación en Red en Enfermedades Cardiovasculares), Javier Fernández‐Portales(Complejo Hospitalario de Cáceres), Javier Jiménez‐Candil(Instituto de Investigación Biomédica de Salamanca), Antonio Hernández‐Madrid, Luís Tercedor(Hospital Universitario Virgen de las Nieves), José Luís Merino(Hospital Universitario La Paz), Pablo Ávila(Hospital General Universitario Gregorio Marañón), F J Fernandez-Aviles(Hospital General Universitario Gregorio Marañón), Fernando Arribas(Hospital Universitario 12 De Octubre)
Cited by 175
Related Papers
Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
|European Journal of Heart Failure|2023|187
Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference
|EP Europace|2022|178
Mechanisms and Drug Development in Atrial Fibrillation
|Pharmacological Reviews|2018|100